Physician profile
Terry Ijeoma Faleye
NPI 1629171764
$243,257.58
in general payments reported to CMS, 2019-2025
38 companies · $82K in 2025
The $82K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14K · 2022: $32K · 2023: $43K · 2024: $72K · 2025: $82K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $111K · Consulting Fee: $41K · Food and Beverage: $22K · Travel and Lodging: $20K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,850 · Education: $638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $110,515.00 |
| Consulting Fee | $41,359.75 |
| Food and Beverage | $22,439.80 |
| Travel and Lodging | $20,353.31 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,849.50 |
| Education | $638.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $52,243.32 | 2021-2025 | |
| Ucb, INC. | $36,632.13 | 2021-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $27,903.40 | 2021-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $25,602.84 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Regeneron Healthcare Solutions, INC. | $24,456.23 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $16,284.89 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $11,624.14 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $9,001.53 | 2023-2025 | Zoryve |
| Incyte Corporation | $7,313.59 | 2021-2025 | Opzelura |
| Janssen Biotech, INC. | $6,494.34 | 2021-2025 | Tremfya, Stelara, Simponi |
| Epi Health, LLC | $5,867.84 | 2021-2022 | |
| Organon LLC | $3,965.17 | 2024-2025 | Vtama |
| Takeda Pharmaceuticals U.S.A., INC. | $3,902.32 | 2025 | |
| Novartis Pharmaceuticals Corporation | $3,828.07 | 2021-2025 | |
| Dermavant Sciences, INC. | $1,788.12 | 2023-2024 | Vtama |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $1,698.11 | 2021-2025 | Adbry, Anzupgo |
| Pfizer INC. | $1,681.56 | 2021-2025 | |
| Amgen INC. | $766.29 | 2021-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $472.66 | 2021-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $452.60 | 2021-2025 | Cabtreo, Jublia, Arazlo |
| Revance Therapeutics, INC. | $268.12 | 2024-2025 | Daxxify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.63 | 2022-2025 | Spevigo, Cyltezo |
| Botanix Sb INC | $112.97 | 2025 | Sofdra |
| Sanofi-Aventis U.S. LLC | $99.00 | 2022 | |
| Verrica Pharmaceuticals INC. | $98.72 | 2023 | Ycanth |
| Hill Dermaceuticals, INC. | $95.75 | 2023-2024 | Tolak |
| Journey Medical Corporation | $67.01 | 2025 | |
| Biocon Biologics INC | $66.17 | 2025 | Yesintek |
| Genentech USA, INC. | $46.38 | 2021 | |
| Biofrontera INC. | $35.64 | 2022-2025 | |
| Springworks Therapeutics, INC. | $33.08 | 2025 | Gomekli |
| Sandoz INC. | $31.38 | 2025 | Hyrimoz |
| Janssen Scientific Affairs, LLC | $24.82 | 2024 | Tremfya |
| Almirall LLC | $23.01 | 2021 | |
| Dermira, INC. | $22.18 | 2021 | |
| Vyne Pharmaceuticals INC. | $16.54 | 2021 | |
| Nobelpharma America, LLC | $15.60 | 2025 | |
| Fidia Pharma USA INC. | $14.43 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Faleye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.